PapersPMID:34420523
Effects of resveratrol supplementation on bone quality: a systematic review and meta-analysis of randomized controlled trials.
resveratrolNo finding here moved its endpoint.
What did not
1 findingHow to read these marks →“As shown in Fig. 4 and Table 3, there were no significant differences between placebo and resveratrol group in the serum biomarkers including ALP (MD: 2.53, 95% CI: − 2.47, 7.52, p = 0.32, 9 studies, 523 participants), BAP (MD: 1.93, 95% CI: − 2.60, 6.47, p = 0.40, 2 studies, 90 participants), CTX (MD: -0.01, 95% CI: − 0.06, 0.03, p = 0.59, 3 studies, 218 participants), OCN (MD: -1.27, 95% CI: − 2.99, 0.46, p = 0.15, 3 studies, 218 participants), PINP (MD: -2.92, 95% CI: − 6.33, 0.50, p = 0.09, 2 studies, 90 participants), and PTH (MD: -0.86, 95% CI: − 1.75, 0.03, p = 0.06, 2 studies, 90 participants).”
- Study
- meta-analysis
- Participants
- 523
- Effect
- 2.53 mean difference, 95% CI −2.47 to 7.52
- Dose studied
- pooled doses 8 mg to 1500 mg daily, oral capsules or tablets
- Population
- adults in 9 pooled RCTs (type 2 diabetes, NAFLD, obesity, healthy elderly and postmenopausal women), resveratrol 8 mg to 1500 mg daily against placebo, 4 weeks to 12 months; some trials with background medication in both arms
Study record
- Design
- meta-analysis
- Species
- human
- Population
- Adults (18 years or older) in 10 RCTs of oral resveratrol vs placebo: postmenopausal women, obese men, type 2 diabetes, NAFLD, healthy elderly and overweight or obese subjects
- Participants
- 698
- Comparator
- placebo
- Duration
- not reported
- Endpoints measured
- 19